1Fradet Y. Molecular and immunologic approaches in the management of bladder cancer. Urol Clin North Am,1991,18:515.
2Sheinfeld J, Reuter VE,Melamed MR, et al. Enhanced bladder cancer detection with the lewis X antigen as a marker of neoplastic transformation. J Urol, 1990,143 t285.
3Tanaka K,Takashi M, Miyake K.et al. Immunocytochemically demonstrated expression, of epithelial membrane antigen and carcinoembryonic antigen by exfoliated urinary cell in patients with bladder cancer. Urol Int, 1994,52 : 140.
4Lonsin A,Fontaniere B. A useful monoclonal antibody(BL2-10Dl) to identify tumor cells in urine cytology, Cancer, 1990, 65:1412.
5Huland E, Huland H, Schneider AW. Quantitative immunocytology in the management of patients with surperficial bladder carcinoma. J Urol,1990,144: 637.
6Klein FA, Detection and follow-up of carcinoma of the urinary bladder by flow cytometry. Cancer,1982,50:389.
7Tailly G, Cornelissen M, Vereecken RL, et al.Urinary carcinoembryogenic antigen (CEA) in the diagnosis and follow-up of bladder carcinoma. Br J Uro1,1983,55:501.
8Halim AB,Ahmady O,Haraza S,et al. Simultaneous determination of urinary CEA, ferritin and TPA in egyptian bladder cancer patients. Int J Biol Markers, 1992,7:234.
9Tizzani A, Casetta G, Cavallini A, et al. Blood and urine determinations of tissue polypeptide antigen in patients with bladder carcinoma. Minerva Urol Netrol,1990,42:69.
10IIes RK, Jenkins BJ, Oliver R ,et al. Beta human chorionic gonadotrophin in serum and urine:a marker for metastatic urothelial cancer. Br J Urol,1989,64:241.
4Lippman SM,Benner SE, Waun KH. Cancer chemoprevention. J Clin Oncol,1994,12(4):851
5Boone CW, Kelloff GJ, Malone WE. Indentification of candidate cancerchemoprevetive agents and their evaluation in animal models and human clinical trials: a review. Cancer Res, 1990, 50: 2
6Sidrnaky D, von Eschenbach A, Tsai YC, et al. Indentification of p53gene mutations in bladder cancer and urine samples. Science, 1991, 252: 706
7Chang HT, Huang JK, Wang JL, et al. Tamoxifen-induced Ca2+ mobilization in bladder female transitional carcinoma cells. Arch Toxicol, 2001,75:184
8Waddle JR, Fine RL, Case BC, et al. Phase 1 and pharmacokinetic analysis of high-dose tamoxifen and chemotherapy in normal and tumor-bearing dogs. Cancer Chemother Pharmacol, 1999, 44: 74
9Ashish MK, Donald LL. Chemoprevention of urological cancer. J Urol, 1999, 161:1748
10Shibata MA, Hasegawa R, Shirai T, et al. Chemoprevention by indomethacin of tumor promotion in a rat urinary bladder carcinogenesis model. Int J Cancer, 1993, 55(6):1011
